肺癌的预后不良,免疫治疗能否从改善患者的免疫功能方面着手进一步改善肺癌的疗效?现将我们的工作小结如下: 一、对象及方法 1、对象:8例为术后患者(7例为Ⅰ期,1例为Ⅱ期),15例为放疗后患者(Ⅱ期晚13人,Ⅲ期2人),13例为化疗患者(Ⅱ期2人,Ⅲ期8人,Ⅳ期3人)。并选择同时期住院的类似病期及病理类型的患者作为对照组。 The prognosis of lung cancer is poor. Can immunotherapy improve the patient’s immune function and further improve the efficacy of lung cancer? Our work is summarized as follows: First, the object and method 1, the object: 8 cases of postoperative patients (7 cases Phase I, 1 case was stage II), 15 patients were post-radiotherapy (13 in late stage II, 2 in stage III), and 13 patients were chemotherapy patients (2 in stage II, 8 in stage III, 3 in stage IV) . Patients with similar stage and pathological types hospitalized in the same period were selected as the control group.